Listen sports fans. CVM is about to have the plant validated...officially. The "other" party knows this, as the FDA has been working with CVM to have this done right.
Once the official "inspection" is done, they also will announce P III trial enrollment (IMO).
Now here's where it gets interesting.
This orphan drug could get quick results (based on what we saw in P II).
Now, we have the manufacturing facility, potentially an approved drug and who to distribute & market it?
Whalla......So yes, a partnership for the distribution in the U.S. is imminent.
No time frame....but imminent. IMO
Enjoy the ride.
Johns Hopkins was involved with teh myocarditis. Why this time do you feel this new arrenagement to test H1n1 brings credibility? Myocarditis went nowhere after impressive results.
Lets face it, LEAPS has been around forever and they pump it for every viral cure known to man. There is no magic bullets. All scientists agree on that one.
Remember they need FDA approval of the drug to sell in the US, but it can be sold in many countries long before FDA approval. Then you may also have a black market of people importing Multikine back to the US to give to cancer patients.
Just remember. Everything must be in place when and if they get approval for use in the U.S. These activities.....shelf for either additional funding or partner stake, money raised, plant validation, collaborations, all play a part in the ultimate goal and must be in place to proceed.
We're finally seeing it all unfold and getting very close to happening.
Other than very tempting trades due to volatility, today's PPS doesn't hint at where it will be 2, 3, 4 years from now.
While everyone is baffled and sniping as to what's going on, do not lose site of what's about to happen. Hours, days, weeks, it doesn't matter.
You want to trade it, fine, but just hold a large core position.
partnership for distribution is a possibity,
The other being that they anticipate a good news to boost to pps and sell on a high volume day to get cash at a low dilution
either case it all good
"Areas of Partnering Interest
Novel technologies for antigen selection, discovery, and identification
Vaccines for Infectious Disease, Cancer, and Respiratory Disease
Novel adjuvants and immunomodulators
Ideally, pre-clinical efficacy or clinical proof of concept achieved"
Hint #2....sounding good?
IMO of course.
"We welcome opportunities for collaboration in areas such as biologics, vaccines, small molecules and technologies.
Our partnerships focus on several important disease areas, including Oncology, Pain, Diabetes, Inflammation and Immunology."
Hint number 1.....:)
IMO of course.